Establishment of the 1^st International Genetic Reference Panel for Factor V Leiden, human gDNA

Summary

Forty-one laboratories participated in an international collaborative study to assess the suitability of a panel of three genomic DNA samples as the 1st International Genetic Reference Panel for the Factor V Leiden (FVL) variant.The code numbers of the materials were 03/254 (FV wild type), 03/260 (FVL homozygote) and 03/248 (FVL heterozygote).The participants evaluated the panel against their in-house controls which were known patient samples and commercial controls. In total, 859 genotype tests were carried out on the panel, with an error rate of 0.7%.The errors were not related to specific samples of the panel or to any specific techniques.The findings of this study have indicated that this panel is suitable to be used as a reference material for genotyping of factor V Leiden. It was therefore recommended that the three genomic DNA samples be established as the 1st International Genetic Reference Panel for Factor V Leiden, Human gDNA, 04/224. This recommendation was approved by the Scientific and Standardization Committee (SSC) of the ISTH (International Society on Thrombosis and Haemostasis) in June 2004 and the Expert Committee on Biological Standardization (ECBS) of theWorld Health Organization (WHO) in November 2004.

Keywords

Factor V Leiden - genetic reference materials - genomic DNA - in vitro diagnostics

• References

• 1 Kalafatis M, Bertina RM, Rand MD. et al. Characterization of the molecular defect in factor V R506Q. J Biol Chem 1995; 270: 4053-7.
• 2 Hillarp A, Zoller B, Dahlback B. Activated protein C resistance as a basis for venous thrombosis. Am J Med 1996; 101: 534-40.
• 3 Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med 1997; 127: 895-903.
• 4 Dahlback B, Hillarp A, Rosen S. et al. Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Ann Hematol 1996; 72: 166-76.
• 5 Rosendaal FR, Koster T, Vandenbroucke JP. et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated proteinC resistance). Blood 1995; 85: 1504-8.
• 6 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-85.
• 7 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 8 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
• 9 Holm J, Zoller B, Berntorp E. et al. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Inter Med 1996; 239: 221-6.
• 10 Emmerich J, Poirier O, Evans A. et al. Myocardial infarction, Arg506 to gln factor V mutation and activated proteinC resistance Letters to the Editor. Lancet 1995; 345: 321.
• 11 Prohaska W, Mannebach H, Schmidt M. et al. Evidence against heterozygous coagulation factor V 1691 G toA mutation with resistance to activated proteinC being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 1995; 73: 521-4.
• 12 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
• 13 Chan LC, Bourke C, Lam CK. et al. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors - correlation with absence of Arg506Gln mutation Letters to the editor. Thromb Haemost 1996; 75: 522-3.
• 14 Ko YL, Hsu TS, Wu SM. et al. The G1691A mutation of the coagulation factor V gene (Factor V Leiden) is rare in Chinese: an analysis of 618 individuals. Hum Genet 1996; 98: 176-7.
• 15 Hu Y, Chen F, Xie Q. et al. No association between thrombosis and factor V gene polymorphisms in Chinese Han population. Thromb Haemost 2003; 89: 446-51.
• 16 Ozawa T, Niiya K, Sakuragawa N. Absence of factor V Leiden in the Japanese Letter to the Editors. Thromb Haemost 1996; 81: 595.
• 17 Hooper WC, Dilley A, Ribeiro MJ. et al. A racial difference in the prevalence of the Arg506Gln mutation. Thromb Res 1996; 81: 577-81.
• 18 World Health Organisation Weekly Epidemiological Record. 2002 77. 197-204.
• 19 Preston FE, Kitchen S, Jennings I. et al. A UK NEQAS for Molecular genetic testing for the Diagnosis of Familial Thrombophilia. Thromb Haemost 1999; 82: 1556-7.
• 20 Tripodi A, Peyvandi F, Chantarangkul V. et al. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations - a cause for concern. Thromb Haemost 2002; 88: 690-1.
• 21 Hertzberg M, Neville S, Favaloro E. et al. External Quality Assurance of DNA testing for Thrombophilia mutations. Am J Clin Pathol. 2005 In press.
• 22 Campbell PJ. International biological standards and reference preparations II: procedures used for the production of biological standards and reference preparations. J Biol Stand 1974; 02: 259-67.